Background: Advanced glycated end products (AGEs) are a heterogeneous group of molecules that were initially discovered at the beginning of the 20th century in the classic Maillard reaction. AGEs have generated interest in the biochemical and medical fields because of their biological effects on humans, particularly ageing. Several studies have associated a decline in physical functioning with higher concentrations of AGEs.
Objective: This study aimed to investigate the possible contribution of advanced glycated end-product levels in motor dysfunction in the elderly.
Material and methods: The study was carried out on 50 older males aged 65 years old and above who presented to the outpatient clinic of the Main University Alexandria Hospital or were admitted to the Geriatric wards, divided into Group I (control) 20 men with normal handgrip strength and normal walking speed (time to walk 3 meters), Group II (cases) 30 men with poor handgrip strength and slow walking speed.
Results: CML levels in group II (cases) ranged from 45.79 – to 101. with a mean value (S.D) of 62.72 ± 12. CML among group I (control) ranged from 49.35 – to 85.50 with a mean value (S. D) of 62.33 ± 7.92.CML was insignificantly higher among the cases group (p=0.390).
Conclusion: There was no statistically significant difference between the serum levels of CML in group II (cases) and the group I (control).